Home Tags Sacituzumab govitecan

Tag: Sacituzumab govitecan

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA)...
Featured image: An aerial view of the Yangtze River Delta/Shanghai in the southern Jiangsu province and northern Zhejiang province. Photo Courtecy: 2015 - 2020 © VCG/Gettyimages. Used with permission.

Everest Medicines to Initiate a Registration Study in China for Sacituzumab...

China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...

FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast...

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer...

Advancements in the Development of ADC-technology for Cancer Treatment

In an article published in Future Drug Discovery, Justyna Mysliwy, Bioconjugation Team Leader at Iksuda Therapeutics, writes about the de developments in the technology...

FDA Accepts Resubmission of Biologics License Application for Sacituzumab Govitecan

Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics License Application (BLA) for sacituzumab...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Immunomedics Resubmits BLA for Sacituzumab Govitecan

In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...

With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...
Gesso Italiano (Italian Chalk) in San Diego's Little Italy neighborhood celebrating its heritage by bringing the vibrancy and flavors of Italy to southern California. Courtesy: 2016 Fotolia.

Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...

Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Sacituzumab Govitecan Achieves 29 Percent ORR in Advanced Urothelial...

Interim data from a 100-patient cohort of cisplatin-eligible patients participating in the TROPHY-U-01, an international, multi-center, open-label, phase II study, in patients with metastatic...